trientine dihydrochloride

ApprovedSmall molecule

UUnivar BV

trientine dihydrochloride is one of 37 small molecule programs targeting Wilson disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Wilson DiseaseActive, not recruiting

Ovarian CancerActive, not recruiting

Wilson DiseaseApproved

Active, not recruiting

Ovarian CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Hycamtin

MMeitheal

Phase 3

28 2

Perjeta

Roche

Phase 3

3 3

Aromasin

Pfizer

Phase 3

2 4

Yondelis

AApotex Inc.

Phase 3

6 5

Liposomal Doxorubicin

Eli Lilly

Phase 3

9 6

Pamiparib

BeiGene

Phase 3

5 7

Sacituzumab Tirumotecan

Merck & Co.

Phase 3

1 8

IV Iron

Pfizer

Phase 3

1 9

SHR-A1811

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

4 10

trientine dihydrochloride

UUnivar BV

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ovarian Cancer1 trial

Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer

Completed·NNational Cheng-Kung University Hospital·Phase 1/2·NCT03480750·18 enrolled

Single Dose1 trial

A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson's Disease Patients

Completed·UUnivar BV·Phase 1·NCT01874028·20 enrolled

Wilson disease1 trial

Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine

Unknown status·UUnivar BV·Phase 4·NCT02426905·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for trientine dihydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — trientine dihydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for trientine dihydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Univar BV company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUnivar BV

trientine dihydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ovarian Cancer1 trial

Single Dose1 trial

Wilson disease1 trial

References

Drug Info

Quick Facts

Related News